{"id":78254,"global_id":"www.cda.org?id=78254","global_id_lineage":["www.cda.org?id=78254"],"author":"8","status":"publish","date":"2026-03-03 09:07:35","date_utc":"2026-03-03 17:07:35","modified":"2026-03-03 09:54:09","modified_utc":"2026-03-03 17:54:09","url":"https:\/\/www.cda.org\/event-details\/goldilocks-and-the-osteoporotic-patient-avoiding-undertreatment-of-dental-disease-is-the-patient-at-risk-for-mronj\/","rest_url":"https:\/\/www.cda.org\/wp-json\/tribe\/events\/v1\/events\/78254","title":"Goldilocks and the Osteoporotic Patient: Avoiding undertreatment of dental disease is the patient at risk for MRONJ","description":"
\n\t

\n\t\t\n\t\t\t\t\t<\/span>\n\n\t\t\t\t\t\n\t\t\t\t @ \t\t\t<\/span>\n\t\t\t\n\t\t\t\t\t\t\t<\/span>\n\t\t\n\t\t\t<\/p>\n<\/div>\n\n\n\n

Anti-resorptive medications provide life-saving and life-enhancing benefits to patients with certain cancers, osteoporosis, and other bone metabolism conditions. Inadequate treatment of dental disease in this patient population may occur due to patient and provider fears of Medication Related Osteonecrosis of the Jaws (MRONJ). This course will review key anti-resorptive pharmacology and physiology, strategies to determine and mitigate risks of developing MRONJ, referral guidelines, general principles of MRONJ management, and abundant patient cases to help participants confidently engage in shared decision-making with their patients.<\/p>\n\n\n\n\n\n\n

\n\t\t\t\tCost: Free for Members; $69 Non-Member<\/span>\n\t<\/div>\n\n\n\n\n
\n\t
\n\t\t

Napa Solano Dental Society<\/a><\/h3>\n\t<\/div>\n\t\t\t

916.634.4211<\/p>\n\t\t\t\t

View Organizer Website<\/a><\/p>\n\t\t<\/div>\n\n\n

\n\t\n\t\t\n
\n\t\n\n<\/iframe>\n<\/div>\n\n\t<\/div>\n\n\n\n\n\n\n\t
\n\t\t
\n\t\t\t